The generic ingredient in CILOSTAZOL is cilostazol. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cilostazol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cilostazol
A generic version of CILOSTAZOL was approved as cilostazol by EPIC PHARMA LLC on November 23rd, 2004.
LOSTAZOL: Investment Scenario, Market Dynamics, and Financial Trajectory
Summary
Cilostazol, a phosphodiesterase III inhibitor primarily used for intermittent claudication, has seen incremental growth driven by expanding indications and regional adoption. This report delineates its investment landscape, evaluates prevailing market forces, projects future financial trajectory, and offers insights for stakeholders. Key drivers include aging populations, cardiovascular health awareness, regulatory shifts, and competitive positioning within the antiplatelet class.
What is Cilostazol?
Attribute
Details
Therapeutic Class
Phosphodiesterase III inhibitor
Primary Indication
Intermittent claudication
Approved Regions
Japan, South Korea, some South American countries
Market Approval Status
Approved for peripheral arterial disease (PAD), with off-label use in other vascular conditions
Key Brands
Pletal (Japan, US), proprietary versions in other regions
What Are the Investment Opportunities for Cilostazol?
Patent Landscape and Market Exclusivity
Patent Status
Key Patents
Expiry Year
Notes
Active
Composition of matter patents (varies regionally)
2025-2030
Patent expiration may open generic entry
Secondary
Use patents for off-label indications
2023-2035
Limited impact due to off-label use
Market Growth Drivers
Driver
Impact
Details
Aging Demographics
High
Increased PAD prevalence among ≥60 years
Cardiovascular Disease Awareness
Moderate
Growing focus on vascular health
Regulatory Pathways
Favorable
Some markets consider regulatory exclusivity extensions
Formulation Innovations
Moderate
Sustained R&D for better delivery systems
Investment Risks
Risk
Impact
Details
Patent Expiry
High
Potential generic competition reduces margins
Competition
High
From other antiplatelets and PAD treatments
Regulatory Changes
Moderate
Stricter approval criteria or off-label restrictions
Pricing Pressures
High
Insurance payers favor cost-effective options
What Is the Current Market Dynamics for Cilostazol?
How does patent expiration affect cilostazol's financial outlook?
Typically results in revenue declines due to generic competition; however, strategic innovations and expanded indications can mitigate this impact.
What regions present the highest investment potential for cilostazol?
Japan and South Korea due to high PAD prevalence and supportive reimbursement environments; emerging markets in Latin America also offer growth opportunities.
Are there ongoing developments to extend cilostazol’s market life?
Yes; research into new formulations, combination therapies, and additional indications aimed at regulatory approval in broader markets.
What competitive strategies can stakeholders adopt amidst increasing generic entry?
Focus on patent extensions, differentiation via formulation, clinical trial data for new indications, and pricing strategies aligned with reimbursement landscapes.
Key Takeaways
Cilostazol remains a relevant asset within vascular pharmacotherapy, with solid regional footholds.
Patent expiries between 2025-2030 pose significant revenue risks; innovation and indication expansion are critical for prolonging its financial viability.
Market dynamics favor growth in aging populations and rising cardiovascular health awareness, especially in Asia and Latin America.
Cost management, regulatory compliance, and strategic R&D are essential to maintaining competitiveness amid increasing generic pressures.
Investors and pharmaceutical companies should monitor patent timelines closely, evaluate regional regulatory policies, and consider lifecycle management strategies.
References
US Food and Drug Administration (FDA). Pletal (cilostazol) prescribing information. 2022.
Japan Pharmaceutical Information Center. Market Reports on Peripheral Arterial Disease (PAD). 2021.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
